TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24862330

Group type: EXPERIMENTAL
Intervention: Aprepitant 125 or 250 mg/d for 2 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aprepitant 375, 625, 750, and 875 mg with exposure enhancement (EE)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aprepitant doses of 875 mg (625 mg with EE) or higher
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 19
Study: 21094553

Group type: EXPERIMENTAL
Intervention: Low-GI diet
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 47
Study: 19462434

Group type: EXPERIMENTAL
Intervention: Tumor M2-PK
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Calprotectin
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Combination of Calprotectin and Tumor M2-PK
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Elevated Calprotectin or Tumor M2-PK
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control (no organic bowel disease)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Functional bowel disease
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Organic bowel disease
Number of subjects: 199
Study: 17578061

Group type: EXPERIMENTAL
Intervention: Structured multidisciplinary quality-of-life (QOL) intervention consisting of eight 90-min sessions addressing cognitive, physical, emotional, spiritual, and social functioning.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard medical care (control group).
Number of subjects: 33
Study: 16624765

Group type: EXPERIMENTAL
Intervention: 20% intralipid (500 ml once a day) from postburn day 4 for 10 consecutive days
Number of subjects: 67

Group type: COMPARATOR
Intervention: Non-intralipid treatment (control group)
Number of subjects: 67
Study: 15025657

Group type: EXPERIMENTAL
Intervention: Ferric oxalate (Sensodyne Sealant)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 11020409

Group type: EXPERIMENTAL
Intervention: Extracapsular cataract extraction with posterior chamber intraocular lens implantation
Number of subjects: 400

Group type: COMPARATOR
Intervention: Each year of increased age
Number of subjects: 400
Study: 8806996

Group type: EXPERIMENTAL
Intervention: Tru‐Close drainage system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hemovac drainage system
Number of subjects: 40
Study: 2005162

Group type: EXPERIMENTAL
Intervention: External fixation (n=21)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conservative treatment (Control group, n=22)
Number of subjects: 101
Study: 6407293

Group type: EXPERIMENTAL
Intervention: 2.5 mg of sustained-release nitroglycerin (SRNG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6.5 mg of sustained-release nitroglycerin (SRNG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30520243

Group type: EXPERIMENTAL
Intervention: Exenatide monotherapy
Number of subjects: 110
Study: 28813878

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) with wrist robot-assisted therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation with wrist robot-assisted therapy
Number of subjects: 24
Study: 26101175

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24339309

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg followed by 0.1 μg/kg/h until the end of surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (volume‐matched normal saline)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study: 23023475

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 19173690

Group type: EXPERIMENTAL
Intervention: 10 ml/kg HES 130/0.42
Number of subjects: 50

Group type: COMPARATOR
Intervention: 10 ml/kg gelatin
Number of subjects: 50
Study: 17502431

Group type: EXPERIMENTAL
Intervention: Indiplon (30, 50, and 80 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25, 0.5, and 0.75 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15143450

Group type: EXPERIMENTAL
Intervention: Theophylline (5-7 mg/kg body weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: nCPAP ventilation
Number of subjects: 60
Study: 11435967

Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg i.v. on days 0 and 4)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study: 9740480

Group type: EXPERIMENTAL
Intervention: valsartan 40 mg twice daily
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: valsartan 80 mg twice daily
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: valsartan 160 mg twice daily
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: lisinopril 5/10 mg once daily
Number of subjects: 116

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 116
Study: 8047822

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily (weekend therapy)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily (Italian study)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily (weekend therapy, Italian study)
Number of subjects: 276
Study: 2854116

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30901302

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus R‐CHOP
Number of subjects: 838

Group type: COMPARATOR
Intervention: Placebo plus R‐CHOP
Number of subjects: 838
Study: 28656129

Group type: COMPARATOR
Intervention: Standard triple therapy (amoxicillin + clarithromycin + omeprazole)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Standard triple therapy plus Bifidobacterium lactis B94 (5 × 10^9 CFU/dose) plus inulin (900 mg) for 14 days
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Standard triple therapy plus Bifidobacterium lactis B94 plus inulin
Number of subjects: 69
Study: 26076572

Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration (7ml of local anesthetic: 4 ml of 0.25% bupivacaine and 3 ml of 2% lidocaine)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration
Number of subjects: 134
Study: 23536132

Group type: EXPERIMENTAL
Intervention: Audit-based education (ABE)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Guidelines and prompts
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 93
Study: 21426271

Group type: EXPERIMENTAL
Intervention: Bleaching with White Smile and bonding with composite resin (G1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bleaching with White Smile, treatment with ascorbic acid and bonding with composite resin (G2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bleaching with White Smile, immersing in artificial saliva for 2 weeks and bonding with composite resin (G3)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bleaching with Opalesence and bonding with composite resin (G4)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bleaching with Opalesence, treatment with ascorbic acid and bonding with composite resin (G5)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bleaching with Opalesence, immersing in artificial saliva for 2 weeks and bonding with composite resin (G6)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (non-bleached specimens)
Number of subjects: 70
Study: 19767078

Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor concentrate at a dose of 20 U/kg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor concentrate at a dose of 10 U/kg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 16832632

Group type: EXPERIMENTAL
Intervention: (11)C-acetate PET
Number of subjects: 32
Study: 15001677

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET scanning in AD patients
Number of subjects: 122

Group type: COMPARATOR
Intervention: (18)F‐FDG PET scanning in healthy elderly subjects (NC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Assessment of coupled rCMRgl reductions between the EC and the ipsilateral T‐O cortex
Number of subjects: 122
Study: 12584828

Group type: EXPERIMENTAL
Intervention: Oxymatrine 0.4 g/d by intramuscular injection for 3 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (liver protecting agents)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oxymatrine treatment
Number of subjects: 44
Study: 10405773

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 22
Study: 8521190

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (0.1 IU/kg/day s.c.)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 32
Study: 2156644

Group type: EXPERIMENTAL
Intervention: 5 mg of bendrofluazide plus inhaled salbutamol (1 mg doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 mg of bendrofluazide plus potassium, magnesium, or triamterene plus inhaled salbutamol (1 mg doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 mg of bendrofluazide plus 50 mg of triamterene plus inhaled salbutamol (1 mg doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo plus inhaled salbutamol (1 mg doses)
Number of subjects: 12
Study: 6249334

Group type: EXPERIMENTAL
Intervention: Guanfacine 3 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clonidine 0.3 mg
Number of subjects: 0
Study: 30387037

Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 446
Study: 28682286

Group type: EXPERIMENTAL
Intervention: Oral diclofenac (50 mg, taken twice daily for 3 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transdermal diclofenac (100 mg, placed once daily for 3 days)
Number of subjects: 20
Study: 26145739

Group type: EXPERIMENTAL
Intervention: Application of expanding transplants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plastic surgery with local tissues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sutural extension of the valve
Number of subjects: 0
Study: 23756302

Group type: EXPERIMENTAL
Intervention: Isolite isolation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cotton roll isolation
Number of subjects: 29
Study: 21554549

Group type: EXPERIMENTAL
Intervention: udenafil 100 mg
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: udenafil 200 mg
Number of subjects: 174

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 174
Study: 19135922

Group type: EXPERIMENTAL
Intervention: Reduced compression mammography (90 N)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard compression mammography (120 N)
Number of subjects: 0
Study: 17509423

Group type: EXPERIMENTAL
Intervention: Telephone-delivered empowerment intervention (EI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standardized HF patient education (Control)
Number of subjects: 90
Study: 15521893

Group type: EXPERIMENTAL
Intervention: linezolid (600 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: moclobemide (300 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 11465311

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 9081124

Group type: EXPERIMENTAL
Intervention: Exclusion technique (EXC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open endoaneurysmorrhaphy (OP)
Number of subjects: 100
Study: 8442965

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopental sodium
Number of subjects: 40
Study: 2878942

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (30 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glucose (placebo)
Number of subjects: 30
Study: 30817785

Group type: EXPERIMENTAL
Intervention: Repeated sprint cycling (fatigue condition)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Countermovement jump height
Number of subjects: 32
Study: 28716796

Group type: EXPERIMENTAL
Intervention: Progressive exercise (≤6 physiotherapy sessions)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Best practice advice (one physiotherapy session)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection then progressive exercise (≤6 sessions)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Corticosteroid injection then best practice advice (one session)
Number of subjects: 704
Study: 26095263

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 82

Group type: COMPARATOR
Intervention: Anti-VEGF injections (control)
Number of subjects: 82
Study: 24174588

Group type: COMPARATOR
Intervention: High third of total cerebral blood flow (CBF)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Low third of total cerebral blood flow (CBF)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Middle third of total cerebral blood flow (CBF)
Number of subjects: 411
Study: 21340655

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) with energy target determined by repeated indirect calorimetry measurements (study group, n = 56)
Number of subjects: 130

Group type: COMPARATOR
Intervention: 25 kcal/kg/day (control group, n = 56)
Number of subjects: 130
Study: 21141017

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with triangular scleral flap (Group A, 11 eyes)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Trabeculectomy with rectangular scleral flap (Group B, 11 eyes)
Number of subjects: 22
Study: 17199546

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg daily for 10 days) with scaling and root planing (SRP) in smokers (Group 3)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg daily for 10 days) with scaling and root planing (SRP) in non-smokers (Group 1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo with scaling and root planing (SRP) in smokers (Group 4)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo with scaling and root planing (SRP) in non-smokers (Group 2)
Number of subjects: 42
Study: 15180807

Group type: EXPERIMENTAL
Intervention: interictal ADC measurement
Number of subjects: 39
Study: 11287757

Group type: EXPERIMENTAL
Intervention: Acute oral protein load in type 2 DM patients without microalbuminuria (MA)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Acute oral protein load in healthy subjects
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Acute oral protein load in type 2 DM patients with microalbuminuria (MA)
Number of subjects: 181
Study: 9386023

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 60
Study: 8485790

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia and analgesia (lidocaine 2% with epinephrine 1:200,000, 20 ml over 30 min; morphine 0.10 mg.kg‐1 after catheter insertion and 0.05 to 0.10 mg.kg‐1 every 12 hr as needed)
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anaesthesia alone (nitrous oxide, oxygen, isoflurane, supplemented with intravenous fentanyl to a maximum of 10 micrograms.kg‐1)
Number of subjects: 20
Study: 3101606

Group type: EXPERIMENTAL
Intervention: Combination of ACNU and Futraful (FT)
Number of subjects: 3421

Group type: EXPERIMENTAL
Intervention: Futraful (FT) only
Number of subjects: 3421

Group type: EXPERIMENTAL
Intervention: Combination of ACNU and FT
Number of subjects: 3421

Group type: EXPERIMENTAL
Intervention: Combination of MMC and FT
Number of subjects: 3421

Group type: EXPERIMENTAL
Intervention: Combination of ADM and FT
Number of subjects: 3421

Group type: COMPARATOR
Intervention: No adjuvant chemotherapy
Number of subjects: 3421

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3421
Study: 2122024

Group type: EXPERIMENTAL
Intervention: Reabilan HN (enteral nutrition)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 19
Study: 1095794

Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 to 1,600 mg daily)
Number of subjects: 885

Group type: COMPARATOR
Intervention: Aspirin (3 to 6 gm daily)
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 885

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 885
Study: 31219558

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone, 300 μg daily for 24 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo patch for 24 weeks
Number of subjects: 90
Study: 27736154

Group type: EXPERIMENTAL
Intervention: Helium/Oxygen (heliox)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Air/O2
Number of subjects: 445
Study: 25263393

Group type: EXPERIMENTAL
Intervention: Rifampicin 450 mg/day for 7 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 24124445

Group type: EXPERIMENTAL
Intervention: Dephytinised fonio porridge (FWFP; 75% fonio-25% wheat)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-dephytinised fonio porridge (FFP)
Number of subjects: 16
Study: 19830425

Group type: EXPERIMENTAL
Intervention: Selective COX-2 inhibitors
Number of subjects: 808

Group type: COMPARATOR
Intervention: Nonselective NSAIDs
Number of subjects: 808
Study: 19464401

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study: 16518320

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) and spectroscopy (MRS) combined with neuropsychological (NP) tests
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: MRI (T1-weighted)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: MRS
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: MRI and NP tests
Number of subjects: 31
Study: 15553595

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1, 40 microg infused twice daily for 28 days (group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Lumbar sympathectomy (group B)
Number of subjects: 86
Study: 10910024

Group type: EXPERIMENTAL
Intervention: BioLogic-DTPF System (hemodiabsorption and push-pull sorbent-based pheresis)
Number of subjects: 0
Study: 9390983

Group type: EXPERIMENTAL
Intervention: Uphill running
Number of subjects: 12

Group type: COMPARATOR
Intervention: Horizontal running
Number of subjects: 12
Study: 8446852

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy for 6 to 24 months
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy
Number of subjects: 134
Study: 3094776

Group type: EXPERIMENTAL
Intervention: Individual approach to seeking consent
Number of subjects: 57

Group type: COMPARATOR
Intervention: Total disclosure of all relevant information
Number of subjects: 57
Study: 31843945

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17160
Study: 28985263

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg daily for 15 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 80
Study: 26932381

Group type: EXPERIMENTAL
Intervention: Post-intubation checklist and time out
Number of subjects: 224
Study: 26576807

Group type: EXPERIMENTAL
Intervention: Minimally invasive thoraco-laparoscopic oesophagectomy (MIO) involving thoracoscopic oesophagectomy and laparoscopic gastric mobilisation with cervical anastomosis.
Number of subjects: 648

Group type: COMPARATOR
Intervention: Open three-stage transthoracic oesophagectomy involving right thoracotomy and laparotomy with cervical anastomosis.
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Minimally invasive thoraco-laparoscopic oesophagectomy (MIO)
Number of subjects: 648

Group type: COMPARATOR
Intervention: Open three-stage transthoracic oesophagectomy
Number of subjects: 648
Study: 23568415

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no TM)
Number of subjects: 21
Study: 20502296

Group type: COMPARATOR
Intervention: Foley balloon inflated to 30 mL
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Foley balloon inflated to 60 mL
Number of subjects: 192
Study: 17823963

Group type: EXPERIMENTAL
Intervention: 480 mg caffeine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Caffeine-free solution (control)
Number of subjects: 74
Study: 16648613

Group type: EXPERIMENTAL
Intervention: Modified diet with Goami No. 2 rice
Number of subjects: 21
Study: 12471278

Group type: EXPERIMENTAL
Intervention: Droperidol (20 mg/kg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg/kg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.2 mg/kg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 101
Study: 9525349

Group type: EXPERIMENTAL
Intervention: Endurance training (3.2 times per week, 50 minutes per session)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Calisthenics training (2.6 times per week, 50 minutes per session)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (light stretching program once a week)
Number of subjects: 105
Study: 7609132

Group type: EXPERIMENTAL
Intervention: Anterior pelvic exenteration
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tumor resection
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pelvic retroperitoneal tumors
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bladder and/or prostate tumors
Number of subjects: 23